This is a contrast between Sol-Gel Technologies Ltd. (NASDAQ:SLGL) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) based on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies Ltd.	N/A	1028.29	32.20M	-1.45	0.00
Sangamo Therapeutics Inc.	84.45M	16.74	68.33M	-0.69	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Sol-Gel Technologies Ltd. and Sangamo Therapeutics Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Sol-Gel Technologies Ltd. and Sangamo Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies Ltd.	0.00%	-54%	-37.9%
Sangamo Therapeutics Inc.	-80.91%	-21.9%	-13.8%

Liquidity

The Current Ratio of Sol-Gel Technologies Ltd. is 16 while its Quick Ratio stands at 16. The Current Ratio of rival Sangamo Therapeutics Inc. is 6.3 and its Quick Ratio is has 6.3. Sol-Gel Technologies Ltd. is better equipped to clear short and long-term obligations than Sangamo Therapeutics Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Sol-Gel Technologies Ltd. and Sangamo Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Sol-Gel Technologies Ltd.	0	0	0	0.00
Sangamo Therapeutics Inc.	0	3	0	2.00

On the other hand, Sangamo Therapeutics Inc.’s potential downside is -15.87% and its consensus price target is $10.5.

Institutional & Insider Ownership

The shares of both Sol-Gel Technologies Ltd. and Sangamo Therapeutics Inc. are owned by institutional investors at 26.4% and 66% respectively. Insiders held 71.84% of Sol-Gel Technologies Ltd. shares. Insiders Competitively, held 0.1% of Sangamo Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Sol-Gel Technologies Ltd.	-0.43%	16.86%	-0.13%	4.48%	-35.13%	16.28%
Sangamo Therapeutics Inc.	11.74%	-13.69%	-15.42%	-39.94%	-57.06%	-12.11%

For the past year Sol-Gel Technologies Ltd. has 16.28% stronger performance while Sangamo Therapeutics Inc. has -12.11% weaker performance.

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.